Status:
RECRUITING
Study of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior Treatment
Lead Sponsor:
Ipsen
Conditions:
Neuroendocrine Tumors
Eligibility:
All Genders
18+ years
Brief Summary
This study will assess how well cabozantinib works and how safe it is in adults with a type of cancer called neuroendocrine tumors (NETs). These tumors can appear in all parts of the body. All partic...
Eligibility Criteria
Inclusion
- Participants can join the study if they meet all of the following conditions:
- Are 18 years or older and able to give informed consent.
- Have a physician-initiated decision to start treatment with cabozantinib for neuroendocrine tumors (NETs), made before joining the study.
- Have unresectable or metastatic, well-differentiated pancreatic (pNET) or extra-pancreatic neuroendocrine tumors (epNET).
- Have already received at least one prior systemic therapy, other than somatostatin analogues.
- Have signed a written informed consent form.
Exclusion
- Participants cannot join the study if:
- They are currently participating in an interventional clinical trial, or have done so within the last 3 months before joining this study.
- They have a contraindication to cabozantinib treatment, based on the product's official prescribing information.
Key Trial Info
Start Date :
December 17 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2028
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT07314164
Start Date
December 17 2025
End Date
December 31 2028
Last Update
February 27 2026
Active Locations (18)
Enter a location and click search to find clinical trials sorted by distance.
1
Medizinische Universitaet Graz
Graz, Austria
2
MVZ am Klinikum Aschaffenburg
Aschaffenburg, Germany
3
Evangelische Lungenklinik Berlin
Berlin, Germany
4
Krankenhaus St. Joseph-Stift Bremen GmbH
Bremen, Germany